Sees FY24 gross margin 49%. Sees FY24 operating loss $215M. Sees FY24 capital expenditures $40M. Sees FY24 year end cash $170M.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TWST:
- These 2 ‘Oversold’ Stocks Could Be Ready for a Comeback, Say Analysts
- Twist Bioscience price target lowered to $37 from $43 at Barclays
- Twist Centogene launch target enrichment panels for rare disease diagnosis
- Twist in research pact with with Astellas, eligible for milestone payments
- Twist Bioscience initiated with Outperform, $33 target at Scotiabank